Medtronic plc delivered its strongest top-line growth performance in more than two years on Tuesday, reporting fiscal third-quarter 2026 results that topped expectations across key metrics and reaffirmed the company's full-year outlook. Revenue rose 8.7% as reported—and 6.0% on an organic basis—to $9.02 billion, coming in 50 basis points ahead of the company's own guidance midpoint and roughly $130 million above the Wall Street consensus estimate of $8.89 billion.
Non-GAAP diluted earnings per share reached $1.36 for the quarter ended January 23, 2026, beating the consensus forecast of $1.33 by three cents. GAAP diluted EPS came in at $0.89. The results represent the company's highest enterprise revenue growth in ten consecutive quarters, a milestone analysts said validated management's multi-year restructuring and innovation investment strategy.
The standout segment was Cardiac Ablation Solutions, which posted revenue growth of 80% year-over-year, including a remarkable 137% increase in the United States alone, driven by surging demand for the company's pulsed field ablation portfolio. The cardiovascular segment as a whole grew 11% year-over-year. Medtronic's surgical robotics, insulin delivery, and neuromodulation businesses also contributed to the broad-based acceleration, signaling a return to durable multi-segment momentum.
Chief Financial Officer Thierry Pieton emphasized disciplined execution alongside the top-line reacceleration: This quarter, we again delivered accelerated growth while investing decisively in our future. We continued to invest in R&D to strengthen our innovation pipeline, funded significant growth opportunities while driving G&A leverage, and executed on our M&A and venture strategy with two key transactions during the period.
Management reiterated its full-year fiscal 2026 guidance, projecting organic revenue growth of approximately 5.5% and non-GAAP diluted EPS of $5.62 to $5.66. The guidance bakes in an estimated $185 million tariff headwind—unchanged from prior guidance—reflecting management's cautious but stable view of the trade policy environment. Excluding the tariff impact, the guidance implies non-GAAP EPS growth of approximately 4.5%.
Medtronic shares opened at $99.57 on Tuesday, trading near the upper end of its 52-week range of $79.55 to $106.33. Several analysts raised price targets following the release, with Barclays maintaining an Overweight rating and a $116 price objective. Needham and Company recently upgraded the stock to Buy with a $121 target, citing the expanding cardiac ablation franchise and favorable surgical robotics positioning as primary catalysts for multiple expansion in the quarters ahead.